Investors might want to brace themselves for a longer-than-anticipated review process. KitePharma had treated more than 200 patients with axi-cel without any cases of fatal brain swelling, and trial data so far strongly suggests the breakthrough therapy is highly effective among patients who currently lack treatment options.Although investors probably don't need to worry about the FDA rejecting the entire axi-cel application in response to a single patient death, it might ask for more safety information before continuing the review process. It's important to remember that no matter how dire a patient's situation is at the start of a trial, the Food and Drug Administrationtakes any patient death during treatment extremely seriously. The event was deemed related to the therapy, but the patient may have been extremely frail to begin with.According to Kite's disclosure, the patient hadn't responded to standard treatments prior to receiving axi-celand displayed symptoms of rapid disease progression. Find the latest Kite Realty Group Trust (KRG) stock quote, history, news and other vital information to help you with your stock trading and investing. The stock closed today at a share price of 0. Two of the patients developed serious CRS, one of whom also experienced multiple organ failures and brain swelling that led to death. Track Kite Pharma (KITE) Stock Price, Quote, latest community messages, chart, news and other stock related information. The latest indifference towards the small price fluctuations of Kite Pharma may raise some interest from shareholders. Looking back at KITE historical stock prices for the last five trading days, on October 13, 2017, KITE opened at 179.79, traded as high as 179.79 and as low as 179.79, and closed at 179.79. Thirty patients were enrolled to evaluate a potential strategy to mitigate effects of cytokine release syndrome (CRS) that arise when therapies such as axi-cel destroy too many cancer cells too quickly. KITE (KITE) has the following price history information. And with the technology about to enter the market, the entry of a big pharma like Gilead seems to have encouraged investors to jump in the space.The patient death is especially surprising because it occurred within a safety expansion cohort the company added to the study supporting its application. The gross proceeds to Kite from the offering, before deducting the underwriting discounts and commissions. (Nasdaq:KITE) today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a price to the public of 69.00 per share. Their counterparts In the US, Juno Therapeutics and Bluebird Bio, are also up, by 18.7% and 8.6%, respectively.īy acquiring Kite Pharma, Gilead is now positioned close to the finish line, along with Novartis, which in July received the unanimous recommendation of an FDA panel for the approval of its CAR-T candidate CTL019. The FDA now has a deadline to make a final decision for Novartis in October, and for Kite in November. 10, 2015 (GLOBE NEWSWIRE) - Kite Pharma, Inc. The stock of the French Celyad, which is working in a version of CAR-T with a wider range of indications, also went up initially by 7%, though it has since retreated to its price before the announcement. The stock of French CAR-T company Cellectis, which is leading the development of an off-the-shelf version of CAR-T, is up by 17% a day after the announcement. Despite the technology’s high patient death toll in clinical trials, the acquisition is widely seen to validate the technology, causing the share price of European companies in the space to increase. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter the final leg of the race to launch the first CAR-T therapy, a technology that is expected to change how cancer is treated. European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |